Papers/PMID:34818350
Antihypertensive effects of rosuvastatin in patients with hypertension and dyslipidemia: A systemic review and meta-analysis of randomized studies.
PloS one2021The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
rosuvastatin — decreases diastolic blood pressure (setting unspecified)
LikelyGrade B, Likely. Human evidence with one recorded weakness, or capped at B by its design or by unread numbers.Finding“The patients treated with rosuvastatin in addition to antihypertensives had a significantly lower DBP (MD = −2.12 mmHg; 95% CI = −3.72 to −0.52; Pfixed-effects model = 0.009; I 2 = 0%, Pheterogeneity = 0.97) than the patients treated with antihypertensives alone.”
Quoted verbatim from Antihypertensive effects of rosuvastatin in patients with hypertension and dyslipidemia: A systemic review and meta-analysis of randomized studies.. - Study
- meta-analysis
- Duration
- 8 weeks
- Dose
- rosuvastatin 20 mg/day
- Population
- Patients with hypertension and dyslipidemia treated with rosuvastatin 20 mg/day plus antihypertensive agents (an ARB, or an ARB plus a calcium channel blocker), compared with the same antihypertensive background alone
Effect -2.12 mean difference, 95% CI -3.72 to -0.52
Antihypertensive effects of rosuvastatin in patients with hypertension and dyslipidemia: A systemic review and meta-analysis of randomized studies.2021PMID:34818350Permalink